Rubella virus vaccine live
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Rubella virus vaccine live
- measles mumps and rubella virus vaccine live
- measles mumps and rubella virus vaccine live mmr
- rubella virus vaccine live
- Rubella virus vaccine live
- ChEMBL ID
- CHEMBL2109225
- RxNorm IDs (RxCUI)
- 762817
- First in class
- No
- Orphan designation
- No
- Drug name stem
- vir-
- Condition
- Meningococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004249
- Subject identifier
- D008589
- Condition
- Chickenpox
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007204
- Subject identifier
- D002644
- Condition
- Measles
- Highest recorded phase
- 2
- Condition identifier
- EFO:1002025
- Subject identifier
- D008457
- Condition identifier
- EFO_0007204
- Highest recorded phase
- 3
- Condition identifier
- EFO_1002025
- Highest recorded phase
- 2
- NCT00109278
- NCT00822237
- NCT03630705
- NCT03691610
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (50)
- A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
- A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
- A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
- Barriers and Facilitators to MMR Vaccination Among Healthcare Workers
- Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live
- Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
- CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
- Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts
- Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)
- Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
- Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
- Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines
- Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines
- Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
- Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients
In development for (3)
- Chickenpox Phase 3
- Measles Phase 2
- Meningococcal infection Phase 3